James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
This is unchanged from the number of companies cited in the previous year.
The citations in the county include:
- Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
- Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
The company cited had to take regulatory and/or administrative actions.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Baxter Healthcare Corporation | Biologics | 10/31/2023 | Equipment Design, Size and Location |
Baxter Healthcare Corporation | Biologics | 10/31/2023 | Cleaning / Sanitizing / Maintenance |
Baxter Healthcare Corporation | Biologics | 10/31/2023 | Absence of Written Procedures |
Baxter Healthcare Corporation | Biologics | 10/31/2023 | In-process conformity - examination, sample testing |
Baxter Healthcare Corporation | Biologics | 10/31/2023 | Lab controls established, including changes |